FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1803829593> ?p ?o ?g. }

• W1803829593 endingPage "51" @default.
• W1803829593 startingPage "5447" @default.
• W1803829593 abstract "Carbonic anhydrase 9 (CA9) has been found to be one of most powerful biomarkers for clear-cell renal cell carcinoma (RCC). The serum CA9 is detectable. The aim of this study was to evaluate the potential prognostic role of serum CA9 in patients with metastatic clear-cell RCC patients under targeted therapy.Serum samples came from the randomized phase 2 TORAVA trial. All patients received a targeted therapy (arm A designed as experimental group: temsirolimus and bevacizumab combination; arm B: sunitinib; arm C: interferon-alfa and bevacizumab). Seventy cases of metastatic clear-cell RCC were analyzed. There were 49 males and 21 females. The age ranged from 33.5 to 79.1 years with a median of 61.2 years. Serum samples were collected before treatment. Serum CA9 was quantified by enzyme-linked immunosorbent assay (ELISA). The correlation of the serum CA9 levels with the clinical parameters, treatment response and overall survival was analyzed. Overall survival estimates were calculated using the Kaplan-Meier method and compared by the log-rank test.Serum concentrations of CA9 ranged between 0 and 897.3 pg/ml, with an average of 94.4±176.6 pg/ml. There was no association between serum CA9 and clinical parameters such as Eastern Cooperative Oncology Group (ECOG) Performance Status (p=0.367) or Motzer classification (p=0.431). The serum CA9 levels were lower in the response group (64.7±104.7 pg/ml) than the no-response group (108.2±203.8 pg/ml), but the difference was not statisticlly significant (p=0.366). For the patient group overall, the Kaplan-Meier survival curve showed that high serum CA9 levels were significantly associated with shorter overall survival (hazard ratio=2.65, 95% confidence interval=1.19-5.92, log-rank test p=0.0136). For the major group of patients treated with temsirolimus and bevacizumab, the Kaplan-Meier survival curve showed that high serum CA9 levels were significantly associated with shorter overall survival (p=0.0006).Serum CA9 levels may be of clinical interest to predict the outcome for patients under targeted therapy for metastatic clear-cell RCC. CA9 may be used to select patients with metastatic clear cell RCC for clinical trials." @default.
• W1803829593 created "2016-06-24" @default.
• W1803829593 creator A5019588141 @default.
• W1803829593 creator A5020353650 @default.
• W1803829593 creator A5029182920 @default.
• W1803829593 creator A5035337866 @default.
• W1803829593 creator A5039365285 @default.
• W1803829593 creator A5046479560 @default.
• W1803829593 creator A5049672639 @default.
• W1803829593 creator A5055176379 @default.
• W1803829593 creator A5061604766 @default.
• W1803829593 creator A5074623695 @default.
• W1803829593 creator A5086252890 @default.
• W1803829593 date "2012-12-01" @default.
• W1803829593 modified "2023-09-26" @default.
• W1803829593 title "Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy." @default.
• W1803829593 cites W1965691258 @default.
• W1803829593 cites W1975950728 @default.
• W1803829593 cites W1989923627 @default.
• W1803829593 cites W1994560434 @default.
• W1803829593 cites W2005067644 @default.
• W1803829593 cites W2017382594 @default.
• W1803829593 cites W2019607817 @default.
• W1803829593 cites W2024586523 @default.
• W1803829593 cites W2025566418 @default.
• W1803829593 cites W2026102934 @default.
• W1803829593 cites W2039722097 @default.
• W1803829593 cites W2052937772 @default.
• W1803829593 cites W2065986098 @default.
• W1803829593 cites W2089787007 @default.
• W1803829593 cites W2099088585 @default.
• W1803829593 cites W2135400147 @default.
• W1803829593 cites W2151365262 @default.
• W1803829593 cites W2156387230 @default.
• W1803829593 cites W2167165074 @default.
• W1803829593 cites W2317231894 @default.
• W1803829593 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23225450" @default.
• W1803829593 hasPublicationYear "2012" @default.
• W1803829593 type Work @default.
• W1803829593 sameAs 1803829593 @default.
• W1803829593 citedByCount "10" @default.
• W1803829593 countsByYear W18038295932013 @default.
• W1803829593 countsByYear W18038295932014 @default.
• W1803829593 countsByYear W18038295932015 @default.
• W1803829593 countsByYear W18038295932017 @default.
• W1803829593 countsByYear W18038295932018 @default.
• W1803829593 countsByYear W18038295932021 @default.
• W1803829593 crossrefType "journal-article" @default.
• W1803829593 hasAuthorship W1803829593A5019588141 @default.
• W1803829593 hasAuthorship W1803829593A5020353650 @default.
• W1803829593 hasAuthorship W1803829593A5029182920 @default.
• W1803829593 hasAuthorship W1803829593A5035337866 @default.
• W1803829593 hasAuthorship W1803829593A5039365285 @default.
• W1803829593 hasAuthorship W1803829593A5046479560 @default.
• W1803829593 hasAuthorship W1803829593A5049672639 @default.
• W1803829593 hasAuthorship W1803829593A5055176379 @default.
• W1803829593 hasAuthorship W1803829593A5061604766 @default.
• W1803829593 hasAuthorship W1803829593A5074623695 @default.
• W1803829593 hasAuthorship W1803829593A5086252890 @default.
• W1803829593 hasConcept C126322002 @default.
• W1803829593 hasConcept C143998085 @default.
• W1803829593 hasConcept C183713625 @default.
• W1803829593 hasConcept C190283241 @default.
• W1803829593 hasConcept C2776694085 @default.
• W1803829593 hasConcept C2776820818 @default.
• W1803829593 hasConcept C2777472916 @default.
• W1803829593 hasConcept C2777802072 @default.
• W1803829593 hasConcept C2779490328 @default.
• W1803829593 hasConcept C55493867 @default.
• W1803829593 hasConcept C71924100 @default.
• W1803829593 hasConcept C75217442 @default.
• W1803829593 hasConcept C86803240 @default.
• W1803829593 hasConcept C90924648 @default.
• W1803829593 hasConceptScore W1803829593C126322002 @default.
• W1803829593 hasConceptScore W1803829593C143998085 @default.
• W1803829593 hasConceptScore W1803829593C183713625 @default.
• W1803829593 hasConceptScore W1803829593C190283241 @default.
• W1803829593 hasConceptScore W1803829593C2776694085 @default.
• W1803829593 hasConceptScore W1803829593C2776820818 @default.
• W1803829593 hasConceptScore W1803829593C2777472916 @default.
• W1803829593 hasConceptScore W1803829593C2777802072 @default.
• W1803829593 hasConceptScore W1803829593C2779490328 @default.
• W1803829593 hasConceptScore W1803829593C55493867 @default.
• W1803829593 hasConceptScore W1803829593C71924100 @default.
• W1803829593 hasConceptScore W1803829593C75217442 @default.
• W1803829593 hasConceptScore W1803829593C86803240 @default.
• W1803829593 hasConceptScore W1803829593C90924648 @default.
• W1803829593 hasIssue "12" @default.
• W1803829593 hasLocation W18038295931 @default.
• W1803829593 hasOpenAccess W1803829593 @default.
• W1803829593 hasPrimaryLocation W18038295931 @default.
• W1803829593 hasRelatedWork W1985416476 @default.
• W1803829593 hasRelatedWork W1995193840 @default.
• W1803829593 hasRelatedWork W2024586523 @default.
• W1803829593 hasRelatedWork W2037837794 @default.
• W1803829593 hasRelatedWork W2063672847 @default.
• W1803829593 hasRelatedWork W2099294889 @default.
• W1803829593 hasRelatedWork W2137381953 @default.

• next